Skip to content
Advertisement
Tech · AI

Eli Lilly CEO David Ricks Says He Uses AI in All His Meetings

David Ricks explains how AI support helps him track research, cut down complexity, and keep pace with the rising demands of modern drug development.

By · 4 min read
Eli Lilly CEO David Ricks Says He Uses AI in All His Meetings
Share

Award-winning Eli Lilly CEO David Ricks has built his leadership style around fast science, rapid decision cycles, and constant curiosity. He now uses artificial intelligence as a core part of that routine.

“I have at least one or two AIs running every minute of every meeting I am in, and I just am asking science questions,” Ricks told Stripe cofounder John Collison during a recent episode of Collison’s “Cheeky Pint” podcast.

He said he uses constant AI support to stay current with new scientific literature. “I read a lot of medical journals. I go to conferences where data is presented,” Ricks said. He added that time with scientists keeps him curious. The goal is simple. He wants fast access to details that help him track early research signals and complex program updates.

His Preferences and Frustrations

David Ricks said he doesn't use OpenAI’s ChatGPT for scientific questions. “It is too verbal,” he said. Instead, he relies on Anthropic’s Claude and xAI’s Grok. He said their style fits his needs far better. “I find it more terse, and the references actually check out more often,” he said.

Even so, David Ricks watches closely for hallucinations. He said frontier models still produce errors in references. “Sometimes the AIs produce references, and they are actually not the thing that they said,” he said. He noted that this forces him to cross-reference details, which takes time.

His endorsement of Grok caught the attention of xAI CEO Elon Musk. Musk wrote on X: “Cool that David Ricks uses @Grok as his daily AI advisor.”

Industry Peers Move Toward AI

AI is also being embraced by other leaders. Microsoft CEO Satya Nadella claimed to summarize Outlook and Teams activity using Copilot when he came to Microsoft's Washington headquarters. Nvidia CEO Jensen Huang claims he relies on AI as a tutor.

To David Ricks, the shift symbolizes pressure within contemporary pharmaceutical research. His role requires rapid digestion of data, constant evaluation of risks, and ongoing scrutiny of scientific signals. These responsibilities are oftentimes faster than traditional review processes.

Barriers To Rapid Drug Discovery

David Ricks said AI remains limited for drug development. He believes science is still far from providing machines with a complete body of biological knowledge. “Probably we need to create the equivalent of what got created with human language, which is a more complete repository of biological knowledge to train against before the machines get a lot better,” he said.

Right now, he believes the field has charted only a fraction of human biology. “I would estimate we might know 10 to 15 percent of human biology,” Ricks said. He added that machines won't reach high performance until knowledge extends well above 50 percent.

Advancing that knowledge would take a massive investment. Ricks claims that new robotics systems are needed to create nonstop experimental data for model training. “That probably requires robotic 24/7 experiments just to create training data sets, and this kind of big lift effort, the kind of thing actually NIH should be doing right now,” he said. He added that such national-scale efforts aren't underway.

Success That Shapes His AI Priorities

Lilly’s rise in global markets has created intense demand for scientific understanding. Shares have climbed roughly 31 percent over the past year. Growth has been driven by Zepbound for weight loss and Mounjaro for diabetes.

These outcomes lie over a wider investment swell. Lilly is increasing production capacity and driving forward massive research in Alzheimer's, cancer, and metabolic disease. These commitments shape how David Ricks structures his workflow. He often points to the scale of the scientific load and the need for constant learning.

He said the company must move fast to support patients who face chronic metabolic conditions. With global projections showing rising obesity rates, David Ricks has placed a long-term focus on GLP-1 treatments and next-generation research that could reach larger groups of patients.

A Leadership Style Built Around Curiosity

Throughout the conversation, David Ricks described curiosity as central to his job. He said he wants brief, reliable information that helps him test assumptions. His use of AI reflects that instinct. He treats AI as a rapid extension of his research habits.

Even with the momentum behind Lilly’s growth, Ricks said AI is still a tool he must watch carefully. It can summarize. It can answer quick questions. It can't replace a thorough scientific review.

For David Ricks, every meeting is a chance to learn something new. A pair of AIs now ride along with him. He says that habit helps him stay prepared for a future that will demand far deeper biological knowledge than the world has today.

Staff Writer

Adriana Nelson is a staff writer covering technology and how it is changing the way businesses work. She writes about artificial intelligence, automation, and the software tools used by small and mid-sized companies. Her stories explain complex technology in plain language, with a focus on what it means for business owners and their teams. Adriana also follows cybersecurity and data privacy. She is based in Austin.

More from Adriana Nelson →

More on Tech

See all Tech →
Entrepreneurs Edit
Read like a founder. Every story, every morning.

Cover stories, founder interviews and The Daily Edit newsletter — the stories founders talk about.

Subscribe Get the newsletter